Lantern Pharma Reports Complete Metabolic Response in Phase 1 LP-284 Trial for Aggressive Lymphoma

Lantern Pharma presented compelling clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma. The patient had previously failed four prior treatment regimens, including CAR-T and bispecific antibody therapies, making this response particularly significant in the context of treatment-resistant disease.

The complete metabolic response was achieved after just two 28-day cycles of LP-284, supporting the drug's synthetic lethal mechanism and its potential to fill a critical post-immunotherapy treatment gap. This development represents a meaningful advancement for patients who have exhausted standard treatment options, including the latest immunotherapies. The response validates Lantern's AI-driven approach to drug development and highlights LP-284's dual potential as both a monotherapy and in combination with FDA-approved agents such as rituximab.

Lantern CEO Panna Sharma emphasized that these results demonstrate the power of the company's RADR AI platform in accelerating oncology drug discovery and development. The platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to solve complex problems in cancer drug development. Additional information about the company's approach is available at https://ibn.fm/LTRN.

The company also noted LP-284's favorable early safety profile, multiple FDA Orphan Drug Designations, and strong intellectual property protection through 2039. These factors position the drug candidate for potential partnership opportunities aimed at expanding hematology portfolios across the pharmaceutical industry. The complete clinical data presentation can be accessed through the full press release at https://ibn.fm/VJkna.

This development carries significant implications for the oncology treatment landscape, particularly for patients with aggressive lymphomas who have limited options after failing immunotherapies. The success of LP-284 could potentially establish a new treatment paradigm for patients with resistant disease and validate the role of artificial intelligence in accelerating the development of targeted cancer therapies. Lantern's growing pipeline of AI-driven therapies spans multiple cancer indications and is estimated to have a combined annual market potential exceeding $15 billion, representing a substantial opportunity to address unmet medical needs in oncology.